Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00233948 · ClinicalTrials.gov registry record · Phase 1
Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma
A Phase 1 study, sponsored by City of Hope Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT00233948 is a Phase 1 study that was terminated before completion, run by City of Hope Medical Center. The registered enrollment target is 29 participants.
The verdict
NCT00233948, a Phase 1 study, was terminated before completion, sponsored by City of Hope Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
RATIONALE: Antiviral drugs, such as nelfinavir mesylate, may help prevent cancer cells from spreading. PURPOSE: This phase I/II trial is studying the side effects and best dose of nelfinavir mesylate and to see how well it works in treating patients with recurrent, metastatic, or unresectable liposarcoma.
Interventions
- GENETIC gene expression analysis
- OTHER laboratory biomarker analysis
- PROCEDURE biopsy
- OTHER pharmacological study
- DRUG nelfinavir mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2006-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00233948
The ClinicalTrials.gov registry entry for NCT00233948 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00233948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00233948 about?
NCT00233948 is a clinical study titled "Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma". RATIONALE: Antiviral drugs, such as nelfinavir mesylate, may help prevent cancer cells from spreading. PURPOSE: This phase I/II trial is studying the side effects and best dose of nelfinavir mesylate and to see how well it works in treating patients with recurrent, metastatic, or unresectable lipos...
What is the current status of trial NCT00233948?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2006-03.
What interventions are being tested in trial NCT00233948?
The interventions under investigation include: gene expression analysis (GENETIC), laboratory biomarker analysis (OTHER), biopsy (PROCEDURE), pharmacological study (OTHER), nelfinavir mesylate (DRUG).
Who is sponsoring clinical trial NCT00233948?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.